Virtual Library
Start Your Search
Yunjian Huang
Author of
-
+
JCSE01 - Perspectives for Lung Cancer Early Detection (ID 779)
- Event: WCLC 2018
- Type: Joint IASLC/CSCO/CAALC Session
- Track: Screening and Early Detection
- Presentations: 1
- Moderators:
- Coordinates: 9/23/2018, 07:30 - 11:15, Room 202 BD
-
+
JCSE01.15 - Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients (ID 14704)
11:15 - 11:15 | Author(s): Yunjian Huang
- Abstract
Background
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3-7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. While the genetic locus of ALK primary point mutations NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring ALK primary point mutations.A total of 339 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of ALK primary point mutation and other genes were detected by next generation sequencing.
ALK gene primary point mutation rate was 8.55% (29/339) in non-small cell lung cancer, including V163L (3 patients), F921Gfs*16 (2 patients), K1416N (2 patients), A585T (2 patients), P1442Q (1 patient), A348T (1 patient), K1525E (1 patient), S737L (1 patient), P115L (1 patient), Q515E (1 patient), E314D (1 patient), R395H (1 patient), S1219F (1 patient), S341G (1 patient), P1543S (1 patient), G129V (1 patient), Q167H (1 patient), L550F (1 patient), T1012M (1 patient), D302Y (1 patient), H755Q (1 patient), H331Q (1 patient), G1474E (1 patient) and E119D (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, 27 patients with co-occurring mutations had a median OS of 20.0 months, and median OS of the 2 patients without complex mutations was 8.5 months. Statistically significant difference was found between the two groups (P=0.02). Briefly, patients with (n=8) or without (n=21) co-occurring EGFR mutations had a median OS of 24.0 months and 20.0 months respectively (P=0.73); patients with (n=21) or without (n=8) co-occurring TP53 mutations had a median OS of 20.0 months and 17.0 months respectively (P=0.83).
EGFR and TP53 gene accompanied may have less correlation with ALK primary point mutation in NSCLC patients. Results of ongoing studies will provide a platform for further research to offer individualized therapy with the purpose of improving outcomes. a9ded1e5ce5d75814730bb4caaf49419
-
+
P1.03 - Biology (Not CME Accredited Session) (ID 935)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 7
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.03-01 - Association of APC Mutations with Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer (ID 11109)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
The role of adenomatous polyposis coli (APC) gene in mitosis might be critical for regulation of genomic stability and chromosome segregation. APC gene mutations have been associated to have a role in colon cancer and since gastric and colon tumors share some common genetic lesions, it is relevant to investigate the role of APC tumor suppressor gene in gastric cancer. While the genetic sites of APC mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring APC mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 294 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of APC mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
APC gene mutation rate was 4.08% (12/294) in non-small cell lung cancer, including R232* (1 patient), Y159* (1 patient), R564* (1 patient), E984Dfs*21 (1 patient), K534Nfs*15 (1 patient), Q161* (1 patient), K1437* (1 patient), K792* (1 patient), T1556Nfs*3 (1 patient), N32S (1 patient), R259W (1 patient) and N372D (1 patient) , and median overall survival (OS) for these patients was 9.0 months. Among them, all patients were APC gene with co-occurring mutation. Briefly, patients with (n=8) or without (n=4) co-occurring EGFR mutations had a median OS of 9.0 months and 6.0 months respectively (P=0.01); patients with (n=6) or without (n=6) co-occurring TP53 mutations had a median OS of 6.5 months and 11.0 months respectively (P=0.04); patients with (n=4) or without (n=8) co-occurring KRAS mutations had a median OS of 16.5 months and 9.0 months respectively (P=0.27); patients with (n=2) or without (n=10) co-occurring CDKN2A mutations had a median OS of 6.5 months and 11.5 months respectively (P=0.68).
8eea62084ca7e541d918e823422bd82e Conclusion
The present study expanded the database on APC gene mutations in NSCLC and enriched the spectrum of known somatic mutations of the APC gene. Chemotherapy may be considered as a possible treatment for carriers of the mutation. EGFR mutated accompanied mutations might play a good prognosis in APC gene mutation NSCLC.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-04 - Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients (ID 11103)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3-7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. While the genetic locus of ALK primary point mutations NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring ALK primary point mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 339 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of ALK primary point mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
ALK gene primary point mutation rate was 8.55% (29/339) in non-small cell lung cancer, including V163L (3 patients), F921Gfs*16 (2 patients), K1416N (2 patients), A585T (2 patients), P1442Q (1 patient), A348T (1 patient), K1525E (1 patient), S737L (1 patient), P115L (1 patient), Q515E (1 patient), E314D (1 patient), R395H (1 patient), S1219F (1 patient), S341G (1 patient), P1543S (1 patient), G129V (1 patient), Q167H (1 patient), L550F (1 patient), T1012M (1 patient), D302Y (1 patient), H755Q (1 patient), H331Q (1 patient), G1474E (1 patient) and E119D (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, 27 patients with co-occurring mutations had a median OS of 20.0 months, and median OS of the 2 patients without complex mutations was 8.5 months. Statistically significant difference was found between the two groups (P=0.02). Briefly, patients with (n=8) or without (n=21) co-occurring EGFR mutations had a median OS of 24.0 months and 20.0 months respectively (P=0.73); patients with (n=21) or without (n=8) co-occurring TP53 mutations had a median OS of 20.0 months and 17.0 months respectively (P=0.83).
8eea62084ca7e541d918e823422bd82e Conclusion
EGFR and TP53 gene accompanied may have less correlation with ALK primary point mutation in NSCLC patients. Results of ongoing studies will provide a platform for further research to offer individualized therapy with the purpose of improving outcomes.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-06 - Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study (ID 11119)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
Mutations of the fibroblast growth factor receptor 1 (FGFR1) is believed to predict response to FGFR inhibitors, but the genetic spectrum of FGFR1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring FGFR1 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 469 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of FGFR1 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
FGFR1 gene mutation rate was 2.99% (14/469) in non-small cell lung cancer, including S99L (3 patients), S107L (2 patients), N546K (1 patient), R756H (1 patient), G70R (1 patient), R661Q (1 patient), V94I (1 patient), R50Q (1 patient), D312V (1 patient), R6Q (1 patient) and M427V (1 patient), and median overall survival (OS) for these patients was 11.4 months. Among them, all patients were FGFR1 gene with co-occurring mutation. Briefly, patients with (n=3) or without (n=11) co-occurring EGFR mutations had a median OS of 16.7 months and 11.0 months respectively (P=0.56); patients with (n=11) or without (n=3) co-occurring TP53 mutations had a median OS of 11.4 months and 20.7 months respectively (P=0.48); patients with (n=2) or without (n=12) co-occurring STK11 mutations had a median OS of 5.0 months and 11.4 months respectively (P=0.57); patients with (n=3) or without (n=11) co-occurring PTCH1 mutations had a median OS of 5.7 months and 11.4 months respectively (P=0.11).
8eea62084ca7e541d918e823422bd82e Conclusion
It demonstrated that FGFR1 mutation was an infrequent genetic alteration, and for firstly, and we found FGFR1 mutation also was an independent delayed adverse prognostic factor only in early stage NSCLC patients, suggesting that FGFR1 mutation may be a viable prognostic factor in these patients.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-07 - A Comparison of Consistency of Detecting HER2 Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients (ID 11114)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
HER2 is expressed in solid carcinomas including cancers of the breast, stomach, lung and pancreas. Preclinical and clinical studies have confirmed that HER2 is a driver gene in non-small-cell lung cancer (NSCLC). Three principal mechanisms of HER2 alteration include: protein overexpression, gene amplification and gene mutations. In NSCLC, HER2 mutations were identified to represent a distinct subset of driver genes that usually excluded with other common driver genes like EGFR, KRAS and ALK, based on published studies. The aim is to detect the consistency of the HER2 gene mutation in peripheral blood and tumor tissue of patients with NSCLC and discuss the clinical application value of HER2 gene mutation in peripheral blood.
a9ded1e5ce5d75814730bb4caaf49419 Method
Real-time fluorescent quantitative PCR was used to determine the HER2 gene mutation of peripheral blood and tumor tissue specimens collected from 185 cases of NSCLC. A comparison of HER2 gene mutation consistency of peripheral blood and tumor tissue specimens was conducted. The correlation between HER2 gene mutations and clinical characteristics of the patients was analyzed.
4c3880bb027f159e801041b1021e88e8 Result
The HER2 gene mutation rate was 3.78% in peripheral blood of 7 patients with NSCLC, and was 2.16% in 4 cancer tissues, the mutation consistency was 75.00% in peripheral blood tumor tissue matched samples. The consistency was statistically significant (κ=0.553, P<0.001). The incidence of HER2 gene mutation in peripheral blood correlate with smoking history (P<0.05)，but did not correlate with age，gender and pathological type (P>0.05)．The incidence of HER2 gene mutation in tumor tissue correlated with gender and smoking history (P<0.05)，but did not correlate with age and pathological type.
8eea62084ca7e541d918e823422bd82e Conclusion
The consistency of the HER2 gene mutation in peripheral blood and tissue is high. HER2 gene mutations of peripheral blood could be used for clinical diagnosis and treatment in cases when tissue specimen is hard to get.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-25 - The Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients (ID 11113)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
The ataxia-telangiectasia mutated kinase protein (ATM) plays a critical role in the cellular response to double strand DNA damage. While the genetic locus of ATM mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring ATM mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 389 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of ATM mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
ATM gene mutation rate was 6.17% (24/389) in non-small cell lung cancer, including L229V (1 patient), V2298E (1 patient), M2041V (1 patient), D126N (1 patient), S2123N (1 patient), Q95L (1 patient), R337H (1 patient), H1474R (1 patient), R772Sfs*25 (1 patient), W488L (1 patient), M1064T (1 patient), E347A (1 patient), K1192R (1 patient), P1374S (1 patient) R248* (1 patient), M1321I (1 patient), I346N (1 patient), H2430R (1 patient), G494D (1 patient), N2282S (1 patient), A1945S (1 patient), E518* plus D1616V (1 patient), Q161* plus E699Q (1 patient) and D2448G plus L2261Tfs*12 (1 patient), and median overall survival (OS) for these patients was 18.0 months. Among them, all patients were ATM gene with co-occurring mutation. Briefly, patients with (n=8) or without (n=16) co-occurring EGFR mutations had a median OS of 21.0 months and 11.0 months respectively (P=0.19); patients with (n=13) or without (n=11) co-occurring TP53 mutations had a median OS of 21.0 months and 14.0 months respectively (P=0.44).
8eea62084ca7e541d918e823422bd82e Conclusion
Although EGFR and TP53 gene accompanied may have less correlation with ATM mutation in NSCLC patients, predict which patients may harbor ATM mutations, could have implications in triaging toward ATM variant identification for potential future targeted therapy. These data have implications for the identification of therapeutic target candidates .
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-27 - Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients (ID 11115)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
The role of BRCA2 gene somatic mutations are mainly to maintain genome integrity in response to DNA damage through different mechanisms. Deregulation of BRCA2 is associated with the development of tumor and altered sensitivity to chemotherapeutic agents, but the genetic variability of BRCA2 somatic mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring BRCA2 somatic mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 362 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of BRCA2 somatic mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
BRCA2 gene somatic mutation rate was 4.97% (18/362) in non-small cell lung cancer, including S547P (2 patients), G1433W (2 patients), I488V (1 patient), C315S (1 patient), T2007S (1 patient), I1929V (1 patient), H3117Y (1 patient), G1370V (1 patient), T768S (1 patient), E2260Q (1 patient), R2087K (1 patient), E3167Q (1 patient), S163T (1 patient), T152I (1 patient), E2275Q (1 patient) and S163T (1 patient) , and median overall survival (OS) for these patients was 18.0 months. Among them, all patients were BRCA2 gene with co-occurring somatic mutation. Briefly, patients with (n=3) or without (n=15) co-occurring EGFR mutations had a median OS of 21.0 months and 18.0 months respectively (P=0.22); patients with (n=11) or without (n=7) co-occurring TP53 mutations had a median OS of 7.5 months and 18.0 months respectively (P=0.15); patients with (n=2) or without (n=16) co-occurring HER2 mutations had a median OS of 11.0 months and 20.0 months respectively (P=0.24).
8eea62084ca7e541d918e823422bd82e Conclusion
BRCA2 mutations represent a distinct subset of NSCLC. NGS might be useful for evaluation of BRCA2 unclassified variants. Our results show that BRCA2 mutations delineate an aggressive subtype of lung cancer for which a targeted treatment through BRCA2 inhibition might offer new opportunities.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P1.03-28 - Association Between Molecular Characteristics of CTNNB1 Mutations and Prognosis in Patients with Nsclc in Chinese Patients (ID 11097)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
Recently, CTNNB1, encoding beta-catenin, is a well-known tumor-related gene in the wnt signaling pathway. While the genetic variability of CTNNB1 mutation NSCLC patients is unclear.The aim of this study is to investigate mutations and prognosis of NSCLC harboring CTNNB1 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 677 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of CTNNB1 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
CTNNB1 gene mutation rate was 1.92% (13/677) in non-small cell lung cancer, including S33F (4 patients), S33C (1 patient), D32H (1 patient), G34R (1 patient), G34V (1 patient), G34del (1 patient), D11G (1 patient), S45P (1 patient), S45F (1 patient) and S45del plus S33Y (1 patient), and median overall survival (OS) for these patients was 12.0 months. Among them, all patients were CTNNB1 gene with co-occurring mutations. Briefly, patients with (n=7) or without (n=6) co-occurring EGFR mutations had a median OS of 25.8 months and 8.5 months respectively (P=0.18); patients with (n=10) or without (n=3) co-occurring TP53 mutations had a median OS of 10.0 months and 17.5 months respectively (P=0.35); patients with (n=2) or without (n=11) co-occurring BRAF mutations had a median OS of 7.5 months and 13.0 months respectively (P=0.14); patients with (n=2) or without (n=11) co-occurring ATM mutations had a median OS of 17.5 months and 11.0 months respectively (P=0.53).
8eea62084ca7e541d918e823422bd82e Conclusion
Accompanied gene has not well been connected with CTNNB1 gene mutations. Our finding expands the mutant spectrum of CTNNB1 gene and adds new understanding of the phenotype.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P1.09 - Pathology (Not CME Accredited Session) (ID 941)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.09-18 - 15 Cases of Clinical and Molecular Features Analysis in Pulmonary Adenoid Cystic Carcinoma (ID 11108)
16:45 - 18:00 | Author(s): Yunjian Huang
- Abstract
Background
Pulmonary adenoid cystic carcinoma (PACC) of the lung is a malignant tumor arising in the tracheobronchial glands distributed in the airway submucosa. The aim of this study is to investigate the molecular characteristics of PACC.
a9ded1e5ce5d75814730bb4caaf49419 Method
From July 2013 to December 2016, 15 PACC patients received treatment. All the patients were diagnosed by pathology. We retrospectively reviewed the clinical data and genetic state.
4c3880bb027f159e801041b1021e88e8 Result
EGFR mutation rate was 6.67% (1/15), and it was 19del, the relationship between EGFR gene status and gender (P=1.000), age (P=1.000), smoking status (P=1.000) and stage (P=1.000) were no significant, and ALK fusion and ROS1 fusion gene was not detected.
8eea62084ca7e541d918e823422bd82e Conclusion
Gene change exists PACC, and the gene detection cannot be ignored in PACC.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.01-104 - EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report (ID 11102)
12:00 - 13:30 | Author(s): Yunjian Huang
- Abstract
Background
The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation. And EGFR-tyrosine kinase inhibitor (TKI) as the standard first line treatment show good response to classical/sensitizing EGFR mutations. With the development of detection methods, some uncommon genomic mutation events such as exon 18-25 kinase domain duplications (KDD) and EGFR rearrangements (EGFR-RAD51 or EGFR-PURB) are found. We reported a case of EGFR-RAD51 fusion in non-small-cell lung cancer(NSCLC) and the efficacy of erlotinib to this type fusion of NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
A 48-year-old male diagnosed with adenocarcinoma (IV, T1N2M1), who was shown to have EGFR fusion by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
The patient with right lung tumor and multiple brain metastases NSCLC. Histological examination of surgical specimens from the brain tumor showed lung adenocarcinoma metastasis. By using next generation sequencing assay, we found that tumor had EGFR-RAD51 fusion rather than the most common kind of EGFR mutations. Then the patient experienced a remarkable tumor response to erlotinib. Considering this rare EGFR fusion and remarkable response to TKI treatment, we conclude that the incidence of EGFR fusions in NSCLC patients should be attentive. NSCLC patients with EGFR-RAD51 fusion gene response to treatment with EGFR inhibitor.
8eea62084ca7e541d918e823422bd82e Conclusion
With the guidance of precise diagnosis, it is important that we should realize other rare EGFR gene mutations and novel diagnostic method.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.03 - Biology (Not CME Accredited Session) (ID 969)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.03-08 - Analysis of ESR1 Mutation Spectrum from Non-Small-Cell Lung Cancer in Chinese Patients (ID 11205)
12:00 - 13:30 | Author(s): Yunjian Huang
- Abstract
Background
A number of studies have documented that estrogen receptor alpha (ESR1) may play an important role in the development and progression of breast cancer. While the genetic variability of ESR1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring ESR1 mutations.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 501 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of ESR1 mutation and other genes were detected by next generation sequencing.
4c3880bb027f159e801041b1021e88e8 Result
ESR1 gene mutation rate was 1.60% (8/501) in non-small cell lung cancer, including V392I (1 patient), H373Y (1 patient), E22K (1 patient), E589Q (1 patient), Q375R (1 patient), N304S (1 patient), G457V (1 patient) and M437I plus M421I (1 patient), and median overall survival (OS) for these patients was 14.0 months. Among them, all patients were ESR1 gene with co-occurring mutation. Briefly, patients with (n=3) or without (n=5) co-occurring EGFR mutations had a median OS of 19.0 months and 6.0 months respectively (P=0.36); patients with (n=4) or without (n=4) co-occurring TP53 mutations had a median OS of 11.0 months and 14.0 months respectively (P=0.45); patients with (n=2) or without (n=6) co-occurring BCRA2 mutations had a median OS of 4.0 months and 19.0 months respectively (P=0.03); patients with (n=3) or without (n=5) co-occurring RB1 mutations had a median OS of 19.0 months and 9.0 months respectively (P=0.47).
8eea62084ca7e541d918e823422bd82e Conclusion
Our results demonstrated that decreased ESR1 gene mutation correlated with poor overall survival in non-small-cell lung cancer patients. ESR1 gene mutation may define a subset of patients with lung cancer appropriate for investigational therapeutic strategies.
6f8b794f3246b0c1e1780bb4d4d5dc53
